Longbow Capital

MessageBird B.V. is a cloud communications platform that provides software solutions for customer communication, including voice services, SMS, email, and two-factor authentication. Founded in 2011 and headquartered in Amsterdam, the company operates additional offices in major cities such as San Francisco, London, and Singapore. MessageBird aims to simplify customer communication by offering a comprehensive suite of APIs that enable enterprises to connect reliably with their global customers. With its own telecommunications carrier infrastructure, MessageBird serves over 15,000 businesses, ensuring fast and dependable communication through SMS, voice, and chat services. The company has garnered significant attention and investment, including a notable $60 million Series A funding round in 2017, underscoring its position as a leading player in the European software industry.

Galatea Technologies specializes in developing a platform that enhances logistics and decision-making processes within the oilfield waste sector. Its primary product, Waste Coordinator, is a software-as-a-service (SaaS) solution that automates and optimizes transportation workflows. This platform facilitates the effective management of waste, water, and emulsion loads by digitizing operations and providing intelligent scheduling and logistics optimization. By automating foundational workflows, Galatea Technologies enables users to maximize operational efficiency, financial performance, and environmental sustainability. Furthermore, it allows users to utilize and market excess capacity at disposal facilities while ensuring compliance with regulatory requirements through digital waste manifesting.

MessageBird B.V. is a cloud communications platform that provides software solutions for customer communication, including voice services, SMS, email, and two-factor authentication. Founded in 2011 and headquartered in Amsterdam, the company operates additional offices in major cities such as San Francisco, London, and Singapore. MessageBird aims to simplify customer communication by offering a comprehensive suite of APIs that enable enterprises to connect reliably with their global customers. With its own telecommunications carrier infrastructure, MessageBird serves over 15,000 businesses, ensuring fast and dependable communication through SMS, voice, and chat services. The company has garnered significant attention and investment, including a notable $60 million Series A funding round in 2017, underscoring its position as a leading player in the European software industry.

Ambicare Health Ltd specializes in developing wearable light sources for medical and consumer healthcare applications. The company offers innovative products such as Ambulight PDT, a light-emitting sticking plaster designed for treating non-melanoma skin cancer using photodynamic therapy, which serves as a non-surgical alternative. Additionally, Ambicare Health provides blue light therapy solutions, including Lustre Pure Light Classic and Lustre Pure Light Pro, which are effective in combating spots and acne. These products are distributed through various channels, including online sales and partnerships with distributors. Founded in 2004 and based in Livingston, United Kingdom, Ambicare Health was formerly known as Lumicure Ltd before rebranding in 2009.

Sky Medical Technology Limited develops innovative neuromuscular electro-stimulation medical devices aimed at enhancing vascular health. Their flagship products include the geko device, which stimulates the common peroneal nerve to activate muscle pumps and improve blood flow, and the firefly device, designed for athletes to enhance lower limb circulation for quicker recovery. The company's OnPulse™ therapy represents a significant advancement in bioelectronic medicine, offering clinically proven solutions for various acute and chronic circulatory conditions, including the prevention of blood clots, treatment of swelling post-surgery, and management of non-healing wounds. These devices are utilized by healthcare professionals, including surgeons, nurses, physiotherapists, and podiatrists, across NHS and private hospitals, as well as in clinical studies. Sky Medical Technology distributes its products globally, reaching markets in Asia, Europe, the Middle East, and North America. Founded in 2006 and based in High Wycombe, United Kingdom, the company addresses the needs of over forty million individuals facing vascular-related health challenges.

Domainex Ltd. is a biotechnology company based in Saffron Walden, United Kingdom, that specializes in contract research and manufacturing services focused on drug discovery. Established in 2001, the company provides a comprehensive range of services, including medicinal and computational chemistry, protein expression and purification, biochemical assay development, and DMPK analysis. Domainex is known for its expertise in developing advanced medicines through innovative technologies, including biochemical binding techniques, particularly for oncology drugs and treatments for inflammatory diseases. The company has a significant emphasis on hit identification and candidate drug synthesis, utilizing both virtual and fragment-based approaches to address complex drug discovery challenges. In 2007, Domainex merged with NCE Discovery, enhancing its capabilities in both biological and chemical research.

Sky Medical Technology Limited develops innovative neuromuscular electro-stimulation medical devices aimed at enhancing vascular health. Their flagship products include the geko device, which stimulates the common peroneal nerve to activate muscle pumps and improve blood flow, and the firefly device, designed for athletes to enhance lower limb circulation for quicker recovery. The company's OnPulse™ therapy represents a significant advancement in bioelectronic medicine, offering clinically proven solutions for various acute and chronic circulatory conditions, including the prevention of blood clots, treatment of swelling post-surgery, and management of non-healing wounds. These devices are utilized by healthcare professionals, including surgeons, nurses, physiotherapists, and podiatrists, across NHS and private hospitals, as well as in clinical studies. Sky Medical Technology distributes its products globally, reaching markets in Asia, Europe, the Middle East, and North America. Founded in 2006 and based in High Wycombe, United Kingdom, the company addresses the needs of over forty million individuals facing vascular-related health challenges.

Calon Cardio-Technology Ltd specializes in the development of implantable micro blood pumps aimed at treating chronic heart failure. The company offers several innovative products, including the MiniVAD, a miniature pump designed to be implanted in the left ventricle of the heart, which helps improve blood supply and alleviate the symptoms associated with heart failure. Additionally, Calon provides the MicroVAD, intended for earlier intervention in patients experiencing progressive heart failure, and the CathVAD, a catheter-delivered micro-pump for managing acute heart failure. Founded in 2007 and based in Swansea, United Kingdom, Calon Cardio-Technology focuses on enhancing patient outcomes through minimally invasive surgical procedures that facilitate the treatment of heart failure.

A spin-out from Imperial Innovations plc and headquartered within the Imperial College Incubator, RepRegen is poised to commercialize the initial product of its hard tissue repair and regeneration platform: StronBoneâ„¢ Bone Graft Substitute. The Company's hard tissue platform is based on 'smart' bioceramics designed to be used, initially, by orthopedic product manufacturers and surgeons. A major RepRegen materials science innovation is the use of Strontium, boosting the performance of the bioceramics.

Ambicare Health Ltd specializes in developing wearable light sources for medical and consumer healthcare applications. The company offers innovative products such as Ambulight PDT, a light-emitting sticking plaster designed for treating non-melanoma skin cancer using photodynamic therapy, which serves as a non-surgical alternative. Additionally, Ambicare Health provides blue light therapy solutions, including Lustre Pure Light Classic and Lustre Pure Light Pro, which are effective in combating spots and acne. These products are distributed through various channels, including online sales and partnerships with distributors. Founded in 2004 and based in Livingston, United Kingdom, Ambicare Health was formerly known as Lumicure Ltd before rebranding in 2009.

PolyTherics has focused on technology development in the area of biomedical polymers for therapeutic applications. The most advanced of its techniques, site-specific PEGylation or TheraPEG, is being exploited in partnership with companies developing biopharmaceuticals. PolyTherics is also committed to developing its own pipeline of optimised clinical candidates.

BioCeramic Therapeutics Ltd. develops medical interventions that enable the body to renew damaged tissues. It offers products to help patients suffering from a range of bone and soft tissue related conditions. BioCeramic Therapeutics Ltd. was formerly known as Advanced Tissue Therapies Ltd. and changed its name to BioCeramic Therapeutics Ltd. in 2007. The company was incorporated in 2006 and is based in London, the United Kingdom.

Sky Medical Technology Limited develops innovative neuromuscular electro-stimulation medical devices aimed at enhancing vascular health. Their flagship products include the geko device, which stimulates the common peroneal nerve to activate muscle pumps and improve blood flow, and the firefly device, designed for athletes to enhance lower limb circulation for quicker recovery. The company's OnPulse™ therapy represents a significant advancement in bioelectronic medicine, offering clinically proven solutions for various acute and chronic circulatory conditions, including the prevention of blood clots, treatment of swelling post-surgery, and management of non-healing wounds. These devices are utilized by healthcare professionals, including surgeons, nurses, physiotherapists, and podiatrists, across NHS and private hospitals, as well as in clinical studies. Sky Medical Technology distributes its products globally, reaching markets in Asia, Europe, the Middle East, and North America. Founded in 2006 and based in High Wycombe, United Kingdom, the company addresses the needs of over forty million individuals facing vascular-related health challenges.

Destiny Pharma is a clinical-stage biotechnology company based in Brighton, United Kingdom, specializing in the discovery and development of innovative antimicrobial medicines aimed at treating infectious diseases. The company is advancing several drug candidates, including XF-73 Nasal, currently in Phase II trials for preventing post-surgical staphylococcal infections, and XF-73 Dermal, which is in Phase I trials for treating skin infections caused by antibiotic-resistant bacteria. Additionally, Destiny Pharma is developing XF-70 for conditions such as ventilator-associated pneumonia and cystic fibrosis, along with DPD-207 for bacterial and fungal eye infections. The company collaborates with various academic institutions and organizations, including the University of Southampton and China Medical System Holdings Limited, to explore new treatments for infections associated with antibiotic resistance. Destiny Pharma's focus on unique mechanisms of action for its XF series presents potential solutions in addressing the growing global healthcare challenge of drug-resistant bacteria.

Biotronics3D, Ltd., established in 2004 and headquartered in London, UK, specializes in developing and marketing innovative software applications for the diagnostic imaging industry. The company's flagship product, 3Dnet Enterprise Suite, is a multi-purpose medical imaging application suite that enables physicians to interact with cross-sectional datasets in 3D space, aiding in the understanding and identification of abnormalities. This suite includes modules for colonoscopy, vessel analysis, and general clinical data analysis. Biotronics3D is certified to ISO 13485 standards and has received FDA 510K clearance and CE marking for its products.

Cyden Limited, established in 2002 and headquartered in Swansea, UK, is a medical device company specializing in the design, manufacture, and distribution of intense pulsed light (IPL) technology devices. Its product portfolio includes the i200+, i300, and i400 series, catering to various salon environments and offering features such as portability, interactive video displays, and user-friendly interfaces. Cyden's IPL devices are used for hair removal treatments and permanent hair reduction, as well as skin treatments like rejuvenation, thread vein removal, and age spot reduction. The company serves customers worldwide through a network of distributors across Africa, America, Asia, Europe, and the Middle East.

Domainex Ltd. is a biotechnology company based in Saffron Walden, United Kingdom, that specializes in contract research and manufacturing services focused on drug discovery. Established in 2001, the company provides a comprehensive range of services, including medicinal and computational chemistry, protein expression and purification, biochemical assay development, and DMPK analysis. Domainex is known for its expertise in developing advanced medicines through innovative technologies, including biochemical binding techniques, particularly for oncology drugs and treatments for inflammatory diseases. The company has a significant emphasis on hit identification and candidate drug synthesis, utilizing both virtual and fragment-based approaches to address complex drug discovery challenges. In 2007, Domainex merged with NCE Discovery, enhancing its capabilities in both biological and chemical research.

PolyTherics has focused on technology development in the area of biomedical polymers for therapeutic applications. The most advanced of its techniques, site-specific PEGylation or TheraPEG, is being exploited in partnership with companies developing biopharmaceuticals. PolyTherics is also committed to developing its own pipeline of optimised clinical candidates.